Search

Search results

317 results found

Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.

Publication: Journal Article

Spetko, Nicholas, Brianna X Wang, Shoshana J Herzig, and Timothy S Anderson. 2024. “Prevalence and Management of Medication Interactions With Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.”. Journal of General Internal Medicine.

The Effect of Singular Nonverbal Behaviours of Experimenters on Pain Reports.

Publication: Journal Article

Daniali, Hojjat, Mollie A Ruben, Per M Aslaksen, Charlotte Fiskum, Ted J Kaptchuk, and Magne A Flaten. 2024. “The Effect of Singular Nonverbal Behaviours of Experimenters on Pain Reports.”. Journal of Pain Research 17: 1345-60.

Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa.

Publication: Working Paper

Stone, J, P Priya, M. Wong, P Stanbrige, N Lee-Walsh, and A Li. Working Paper. “Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa..”

Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa.

Publication: Working Paper

Stone, J, P Priya, M. Wong, P Stanbrige, N Lee-Walsh, and A Li. 2020. “Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa..”

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Publication: Journal Article

Alter, Galit, Jingyou Yu, Jinyan Liu-, -Kathryn E. Stephenson-, -Hanneke Schuitemaker, and Dan H. Barouch. 2021. “Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans”. Nature 596 (7871): 268-72.

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound

Publication: Journal Article

Offersen, Rasmus, Wen-Han Yu, Eileen P. Scully-, -Kathryn E. Stephenson-, -Ole S. Sogaard, and Galit Alter. 2020. “HIV Antibody Fc N-Linked Glycosylation Is Associated With Viral Rebound”. Cell Reports 33 (11): 108502.

Triple bNAb cocktail provides long-term virologic control in people with HIV

News: March 04, 2024

Key takeaways: Eighty-three percent of patients maintained virologic suppression after the bNAb cocktail for 28 weeks. Forty-two percent had virologic suppression for 38 to 44 weeks despite the decline of bNAb concentrations.

NIH launches clinical trial of three mRNA HIV vaccines

News: March 14, 2022

Phase 1 study is among first to examine mRNA technology for HIV.

Harvard Medical Grand Rounds on Pandemic Preparedness (Video)

News: April 04, 2024

Harvard Medical Grand Rounds Pandemic Preparedness Kathryn E. Stephenson, MD, MPH Associate Professor of Medicine, Harvard Medical School Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Infectious Disease Surveillance Jacob Lemieux, MD, PhD Assistant Professor of...

Ariana Leonelli, MSc

Person: Clinical Research Coordinator

Ariana graduated from American University in 2016 with a BSc in Public Health. As an undergraduate student, she uncovered a passion for infectious and communicable disease prevention. After spending a couple years living in Germany to learn the culture and language, she pursued her MSc in London at...